Evidence map›Paper›PMID 25049085›Full record

ReviewAdvanced drug delivery reviews2015

Coaxing stem cells for skeletal muscle repair.

Karl J A McCullagh, Rita C R Perlingeiro

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Porous biomaterial scaffolds for skeletal muscle tissue engineering.Frontiers in bioengineering and biotechnology · 2023
    Review
  3. Article
  4. Review
  5. Bioinks and Bioprinting Strategies for Skeletal Muscle Tissue Engineering.Advanced materials (Deerfield Beach, Fla.) · 2022
    Review
  6. Article
  7. Current Strategies for the Regeneration of Skeletal Muscle Tissue.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cell therapy to improve regeneration of skeletal muscle injuries.Journal of cachexia, sarcopenia and muscle · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Karl J A McCullaghDepartment of Physiology, School of Medicine and Regenerative Medicine Institute, National University of Ireland Galway, Ireland.
Rita C R PerlingeiroLillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Electronic address: perli032@umn.edu.

Funding

Skeletal Muscle Regeneration from Differentiating Pluripotent Stem CellsR01AR055299 · NIAMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2008 to 2018
$3.3M
Examining the Therapeutic Potential of iPS cells in Duchenne Muscular DystrophyRC1AR058118 · NIAMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2010 to 2010
$1000k
NIAMS NIH HHS R01 AR055299NIAMS NIH HHS RC1 AR058118NIAMS NIH HHS RC1AR058118
6 · The paper itself

Abstract

Skeletal muscle has a tremendous ability to regenerate, attributed to a well-defined population of muscle stem cells called satellite cells. However, this ability to regenerate diminishes with age and can also be dramatically affected by multiple types of muscle diseases, or injury. Extrinsic and/or intrinsic defects in the regulation of satellite cells are considered to be major determinants for the diminished regenerative capacity. Maintenance and replenishment of the satellite cell pool is one focus for muscle regenerative medicine, which will be discussed. There are other sources of progenitor cells with myogenic capacity, which may also support skeletal muscle repair. However, all of these myogenic cell populations have inherent difficulties and challenges in maintaining or coaxing their derivation for therapeutic purpose. This review will highlight recent reported attributes of these cells and new bioengineering approaches to creating a supply of myogenic stem cells or implants applicable for acute and/or chronic muscle disorders.

Indexed as

HumansMuscle, SkeletalRegenerationSatellite Cells, Skeletal MuscleStem Cell TransplantationBioengineeringMesenchymal stem cellsMuscle regenerationMuscular dystrophyNichePluripotent stem cellsSatellite cells

Identifiers

PMID25049085
PMCPMC4295015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.